Sahar Rahimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sahar Rahimi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Ali Derakhshani
Research Center for Hydatid Disease in Iran Kerman University of Medical Sciences Kerman Iran
1 shared publication- Foruzan Delavarian
Department of Internal Medicine, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication Nader Shahrokhi
Department of Physiology and Pharmacology, Physiology Research Center Kerman University of Medical Sciences Kerman Iran
1 shared publication- Nader Shahrokhi
Department of Physiology and Pharmacology, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Nazgol Sharifi
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Sara Shafieipour
Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication
Latest Publications
- Open Access
- 9 June 2026
- Published by Wiley in Animal Models and Experimental Medicine
Cell therapy comparison of dental pulp stem cells, hepatocytes, and their exosomes for liver fibrosis treatment in rats
Background: Excessive extracellular matrix accumulation, primarily as a result of hepatic stellate cell activation, is a hallmark of hepatic fibrosis, a progressive outcome of chronic liver injuries. Recent research studies suggest that stem cells, hepatocytes, and extracellular vesicles may provide therapeutic advantages due to their anti‐inflammatory, antioxidative, and regenerative activities. This study aimed to comparatively evaluate the therapeutic efficacy of these agents in a rat model of carbon tetrachloride (CCl 4 )–induced hepatic fibrosis. Methods: Liver fibrosis was induced in male Wistar rats via intraperitoneal CCl 4 injections for 8 weeks. Then the animals were intravenously administrated stem cells, hepatocytes, hepatocyte‐derived exosomes, or stem cell–derived exosomes. Also, a fibrosis, a sham, a intact, and a PBS‐treated group were consider the controls. After treatment, protein expression (alpha‐smooth muscle actin (α‐SMA), desmin), oxidative stress markers (superoxide dismutase, glutathione peroxidase, malondialdehyde), serum biochemical parameters (aspartate aminotransferase, alanine aminotransferase, glucose, uric acid, cholesterol, triglycerides), and fibrosis‐related gene expression (matrix metalloproteinase 2 (MMP2) , platelete‐derived growth factor receptor beta ( PDGFRB ), transforming growth factor‐beta ( TGF‐β ), thymosin beta‐10 ( TMSB10) and transmembrane protein 176B (TMEM176B) ) were assessed. Results: Significant liver damage, changed metabolic parameters, increased oxidative stress, and upregulated fibrosis markers were all observed in the fibrosis group. On the contrary, all treatments caused considerable improvements, though exosomes derived from stem cells demonstrated the most significant effects. Along with improved histopathological features, this group exhibited significant decreases in oxidative damage, liver enzymes, and profibrotic marker expression. Conclusion: Liver fibrosis was considerably reduced by stem cells, hepatocytes, and particularly their exosomes. Exosomes made from stem cells demonstrated the strongest therapeutic effect, confirming their potential as a viable noncellular hepatic fibrosis treatment approach.
- 9 June 2026
- Published by Wiley in Animal Models and Experimental Medicine
Open AccessCell therapy comparison of dental pulp stem cells, hepatocytes, and their exosomes for liver fibrosis treatment in rats
Background: Excessive extracellular matrix accumulation, primarily as a result of hepatic stellate cell activation, is a hallmark of hepatic fibrosis, a progressive outcome of chronic liver injuries. Recent research studies suggest that stem cells, hepatocytes, and extracellular vesicles may provide therapeutic advantages due to their anti‐inflammatory, antioxidative, and regenerative activities. This study aimed to comparatively evaluate the therapeutic efficacy of these agents in a rat model of carbon tetrachloride (CCl 4 )–induced hepatic fibrosis. Methods: Liver fibrosis was induced in male Wistar rats via intraperitoneal CCl 4 injections for 8 weeks. Then the animals were intravenously administrated stem cells, hepatocytes, hepatocyte‐derived exosomes, or stem cell–derived exosomes. Also, a fibrosis, a sham, a intact, and a PBS‐treated group were consider the controls. After treatment, protein expression (alpha‐smooth muscle actin (α‐SMA), desmin), oxidative stress markers (superoxide dismutase, glutathione peroxidase, malondialdehyde), serum biochemical parameters (aspartate aminotransferase, alanine aminotransferase, glucose, uric acid, cholesterol, triglycerides), and fibrosis‐related gene expression (matrix metalloproteinase 2 (MMP2) , platelete‐derived growth factor receptor beta ( PDGFRB ), transforming growth factor‐beta ( TGF‐β ), thymosin beta‐10 ( TMSB10) and transmembrane protein 176B (TMEM176B) ) were assessed. Results: Significant liver damage, changed metabolic parameters, increased oxidative stress, and upregulated fibrosis markers were all observed in the fibrosis group. On the contrary, all treatments caused considerable improvements, though exosomes derived from stem cells demonstrated the most significant effects. Along with improved histopathological features, this group exhibited significant decreases in oxidative damage, liver enzymes, and profibrotic marker expression. Conclusion: Liver fibrosis was considerably reduced by stem cells, hepatocytes, and particularly their exosomes. Exosomes made from stem cells demonstrated the strongest therapeutic effect, confirming their potential as a viable noncellular hepatic fibrosis treatment approach.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Inflammation
- Vol. 2025 (1)
The Protective Effect of Geraniol Against Hepatic Ischemia–Reperfusion Injury by Attenuating Oxidative Stress, Inflammatory Response, and Apoptosis in Rat Model
Background: Hepatic ischemia–reperfusion injury (HIRI) is one of the main causes of hepatic fibrosis that occurs during liver surgery. This study aimed to investigate the protective effect of geraniol (GNL) against HIRI in a rat model. Methods: Wistar rats were randomly divided into seven groups and subjected to 45 min of hepatic ischemia, followed by either 60 min or 6 h of reperfusion. Immediately before reperfusion, graded doses of geraniol (50 and 100 mg/kg) were administered intraperitoneally. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured to evaluate liver function. Antioxidant enzyme activities were assessed in liver homogenates. The concentrations of TNF‐α, IL‐1β, Bax, and Bcl2 mRNA and proteins in liver tissue were measured using RT‐PCR and enzyme‐linked immunosorbent assay (ELISA). The expression of Bcl2 and caspase‐3 in liver tissue was evaluated by immunohistochemistry. In addition, liver tissue histopathology was examined under a light microscope. Results: The results demonstrated that liver damage significantly increased after repeated HIRI. However, treatment with GNL reduced hepatic enzyme levels and mitigated pathological changes resulting from repeated HIRI. Additionally, GNL treatment led to a decrease in apoptotic factors. Conclusion: GNL may be a potential therapeutic agent for preventing or treating hepatic fibrosis caused by ischemia–reperfusion injury.
- 1 January 2025
- Published by Wiley in International Journal of Inflammation
- Vol. 2025 (1)
Open AccessThe Protective Effect of Geraniol Against Hepatic Ischemia–Reperfusion Injury by Attenuating Oxidative Stress, Inflammatory Response, and Apoptosis in Rat Model
Background: Hepatic ischemia–reperfusion injury (HIRI) is one of the main causes of hepatic fibrosis that occurs during liver surgery. This study aimed to investigate the protective effect of geraniol (GNL) against HIRI in a rat model. Methods: Wistar rats were randomly divided into seven groups and subjected to 45 min of hepatic ischemia, followed by either 60 min or 6 h of reperfusion. Immediately before reperfusion, graded doses of geraniol (50 and 100 mg/kg) were administered intraperitoneally. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured to evaluate liver function. Antioxidant enzyme activities were assessed in liver homogenates. The concentrations of TNF‐α, IL‐1β, Bax, and Bcl2 mRNA and proteins in liver tissue were measured using RT‐PCR and enzyme‐linked immunosorbent assay (ELISA). The expression of Bcl2 and caspase‐3 in liver tissue was evaluated by immunohistochemistry. In addition, liver tissue histopathology was examined under a light microscope. Results: The results demonstrated that liver damage significantly increased after repeated HIRI. However, treatment with GNL reduced hepatic enzyme levels and mitigated pathological changes resulting from repeated HIRI. Additionally, GNL treatment led to a decrease in apoptotic factors. Conclusion: GNL may be a potential therapeutic agent for preventing or treating hepatic fibrosis caused by ischemia–reperfusion injury.